

Zambia ALMA Quarterly Report Quarter Two, 2025



Scorecard for Accountability and Action





Malaria is endemic in all parts of Zambia and transmission is seasonal. The annual reported number of malaria cases in 2022 was 8,318,534 with 1361 deaths.

Key



Zambia ALMA Quarterly Report Quarter Two, 2025



Malaria

Africa is at the centre of a perfect storm that threatens to disrupt malaria services and undo decades of progress. Countries must act urgently to both prevent and mitigate the adverse effects of the ongoing global financial crisis, decreasing ODA, increasing biological threats, climate change, and humanitarian crises. These threats represent the most serious emergency facing malaria in 20 years and will lead to malaria upsurges and epidemics if not addressed. To get back on track and eliminate malaria, US\$5.2 billion is needed annually to fully finance country national malaria plans, and urgently fill gaps created by the recent reductions in ODA. Extreme weather events and climate change present a significant threat. Africa is disproportionately exposed to the risks of climate change and by the 2030s, 150 million additional people will be at risk of malaria because of warmer temperatures and increased rainfall. Extreme weather events displace millions and destroy roads and health facilities, reducing access to health services. Countries must also take action to confront the threats of insecticide and drug resistance, reduced efficacy of rapid diagnostic tests, and the invasive Anopheles stephensi mosquito which spreads malaria in both urban and rural areas. The good news is that the malaria toolkit continues to expand. WHO has approved the use of dual-insecticide mosquito nets that are 43% more effective than traditional mosquito nets and will address the impact of insecticide-resistance. New medicines for treating malaria and two malaria vaccines for children have also been approved with an increasing number of countries deploying these new tools. Malaria can serve as a pathfinder for primary health care strengthening, climate change and health, and Universal Health Coverage. Countries must work to sustain and increase domestic resource commitments including through multisectoral End Malaria and NTD Councils and Funds, which have raised over US\$150 million to date.

Progress

Zambia has carried out insecticide resistance monitoring since 2015 and reported the results to WHO and in response to high levels of resistance has rolled out next generation nets and insecticides. Zambia has launched the Malaria Ends with Me campaign.

In line with the priority agenda of the ALMA chair, President Advocate Duma Gideon Boko, Zambia has enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Control and Elimination Scorecard and the sharing of the country scorecards through the ALMA Scorecard Hub. The country has also launched the multisectoral high level End Malaria Council and Malaria Fund and the Zambia youth corps.

Impact

The annual reported number of malaria cases in 2022 was 8,318,534 with 1361 deaths.

Key Challenges

- The country has documented mosquito resistance to four insecticide classes.
- Suspected artemisinin partial resistance.
- There is a need to strengthen cross border collaboration with neighbouring countries.
- The country has significant resource gaps, including with the impact of the recent reductions in ODA

Previous Key Recommended Actions

	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
'	Track the implications of the US Government actions related to PMI support and work to mitigate the impact	Q4 2025		In 2025, the National Malaria Elimination Centre (NMEC) secured procurement commitments for malaria case management commodities from the Government, Global Fund, and PMI. However, PMI's sudden and unexpected temporary 90-day suspension of support disrupted the supply pipeline. To address this, the Government advanced its procurement schedule. Despite delays in delivery, ACT treatment coverage remained high at 96% with only a few districts reporting a temporary stockout, and the Government met its full funding commitment for RDTs and ACTs. Additionally, the restructuring of ZAMMSA improved procurement efficiency, enabling the acquisition of WHO-prequalified commodities at reduced costs. Following the suspension period, PMI resumed support, and Zambia currently has sufficient ACTs and RDTs for 2025. Looking ahead to 2026, no commitments have been confirmed, resulting in a projected funding gap of USD 17.3 million. PMI's IRS support for 2024/2025 spray season was completed before the PMI 90-day funding suspension. The 2026 mass bednet campaign has been fully funded with support from government, Global Fund and Against Malaria Foundation (AMF). Following the resumption, USG will no longer support Entomological surveillance and Socio-behaviour communication (SBC). PMI supported four selected provinces through PAMO+. This project was closing in September 2025 and new call for proposals advertised. Following the funding suspension, staff in the provinces were laid off and activities cancelled. This has led to critical staffing shortages in the provinces. There is no indication of a follow-on project.

Zambia has responded to the previous recommended action on drug resistance monitoring and continues to track progress as the identified actions are implemented.

New Key Recommended Action

Objective	Action Item	Suggested completion timeframe
Impact	Work to address low stocks of RDTs	Q3 2025

Reproductive, Maternal, Newborn, Adolescent and Child Health

Progress

Zambia has achieved high coverage in the tracer RMNCAH intervention DPT3. The country has also increased coverage of ARTs in children. Zambia has enhanced accountability mechanisms with the development of a Reproductive, Maternal, Newborn and Child Health Scorecard.

Neglected Tropical Diseases

Progress

Progress in addressing Neglected Tropical Diseases (NTDs) in Zambia is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, schistosomiasis, soil transmitted helminths and trachoma. In 2023, preventive chemotherapy coverage was 66% for schistosomiasis, 5% for Soil transmitted helminthiasis, 0% for trachoma and 100% for lymphatic filariasis. Overall, the NTD preventive chemotherapy coverage index in 2023 is 8 which represent an increase compared to the 2022 index value (3). The country reached the WHO MDA coverage target only for lymphatic filariasis.

Previous Key Recommended Actions

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Climate Change and health	Work to collate data on the impact of climate change on Vector Borne disease and incorporate into the next round on National Determined Contributions and National Climate Change Action Plans	Q4 2025		Deliverable not yet due
NTDs	Submit data to the AUC on the national Budget Allocated to NTDs	Q4 2025		The country has no specific budget line for NTDs and most of the NTD interventions are donor supported. Case management for some NTDs is integrated into primary health care.

